Earnings Releases·Nov 10, 2026, 6:54 AM ET

Protalix BioTherapeutics — Third Quarter 2026 Earnings Summary

Total revenues for the nine months ended September 30, 2026, reached $75.6 million, a 73% increase from $43.6 million in the prior year period, driven by a $25.0 million milestone payment from Chiesi and higher sales to Chiesi.
Net income turned positive for the nine-month period at $26.1 million ($0.33 basic per share), compared to a net loss of $1.1 million in 2025, while Q3 net income rose to $4.0 million ($0.05 per share) from $2.4 million in the prior year quarter.
Management expects to meet or exceed full-year 2026 revenue guidance of $78.0 million to $83.0 million, with Elfabrio sales projected between $33.0 million and $35.0 million and Elelyso sales between $20.0 million and $23.0 million.
The company maintains a strong balance sheet with $48.5 million in cash, cash equivalents, and short-term bank deposits, and holds no outstanding debt or warrants.
Strategic progress includes the ongoing Phase 2 RELEASE study for PRX-115 with top-line results anticipated in H2 2027, alongside new marketing authorization for Elfabrio in Brazil for both every-two-weeks and every-four-weeks dosing regimens.